Energizing industry optimization, intelligent upgrading and green development
03
2022/09
2022.09.07
Polypropylene infusion bottle packaging metronidazole sodium chloride injection approved
After obtaining the approval documents for the production of Agatroban API and the first approved azithromycin dry suspension in China, Shijiazhuang No.4 Pharmaceutical Group achieved another success in product development.
2022.09.07
SJZ No.4 Pharmaceutical Agatroban API approved
Recently, Agatroban, which was declared by Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang No.4 Pharmaceutical Group, was approved by the State Drug Administration to be registered as an API for listed preparations.
2022.09.05
Azithromycin dry suspension was approved for the first time in China
Recently, the azithromycin dry suspension developed by Shijiazhuang No.4 Pharmaceutical Co., Ltd. obtained the drug registration certificate issued by the State Drug Administration
Pursue "green" and integrate development
17
2022/08
Innovation leads the cohesion "butterfly change"
15
2022/08
Previous page
1
Next page
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Copyright © 2021 SJZ No.4 Pharmaceutical 冀ICP备05007979号-1